Bausch + Lomb Corporation – TSX:BLCO.TO
Bausch + Lomb stock price today
Bausch + Lomb stock price monthly change
Bausch + Lomb stock price quarterly change
Bausch + Lomb stock price yearly change
Bausch + Lomb key metrics
Market Cap | 8.97B |
Enterprise value | 9.92B |
P/E | 746.67 |
EV/Sales | 2.63 |
EV/EBITDA | 16.84 |
Price/Sales | 2.08 |
Price/Book | 1.11 |
PEG ratio | -7.76 |
EPS | -0.96 |
Revenue | 4.31B |
EBITDA | 511M |
Income | -337M |
Revenue Q/Q | 18.04% |
Revenue Y/Y | 13.22% |
Profit margin | 0.16% |
Oper. margin | 5.49% |
Gross margin | 59.69% |
EBIT margin | 5.49% |
EBITDA margin | 11.85% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBausch + Lomb stock price history
Bausch + Lomb stock forecast
Bausch + Lomb financial statements
| Jun 2023 | 1.03B | -32M | -3.09% |
|---|---|---|---|
| Sep 2023 | 1.00B | -84M | -8.34% |
| Dec 2023 | 1.17B | -54M | -4.6% |
| Mar 2024 | 1.09B | -167M | -15.2% |
| Dec 2023 | 1.17B | -54M | -4.6% |
|---|---|---|---|
| Mar 2024 | 1.09B | -167M | -15.2% |
| Sep 2025 | 1.69B | 90.34M | 5.34% |
| Dec 2025 | 1.83B | 108.82M | 5.93% |
Analysts Price target
Financials & Ratios estimates
| 2024-02-21 | 0.18 | 0.24 |
|---|---|---|
| 2024-05-01 | 0.05 | 0.07 |
| Jun 2023 | 11315000000 | 4.28B | 37.87% |
|---|---|---|---|
| Sep 2023 | 13068000000 | 6.18B | 47.33% |
| Dec 2023 | 13442000000 | 6.52B | 48.52% |
| Mar 2024 | 13293000000 | 6.56B | 49.38% |
| Jun 2023 | -24M | -28M | 90M |
|---|---|---|---|
| Sep 2023 | 48M | -1.88B | 1.81B |
| Dec 2023 | 15M | -135M | 86M |
| Mar 2024 | 41M | -57M | 12M |
Bausch + Lomb alternative data
| Aug 2023 | 12,900 |
|---|---|
| Sep 2023 | 13,000 |
| Oct 2023 | 13,000 |
| Nov 2023 | 13,000 |
| Dec 2023 | 13,000 |
| Jan 2024 | 13,000 |
| Feb 2024 | 13,000 |
| Mar 2024 | 13,300 |
| Apr 2024 | 13,300 |
| May 2024 | 13,300 |
| Jun 2024 | 13,300 |
| Jul 2024 | 13,300 |
Bausch + Lomb other data
-
What's the price of Bausch + Lomb stock today?
One share of Bausch + Lomb stock can currently be purchased for approximately $20.85.
-
When is Bausch + Lomb's next earnings date?
Unfortunately, Bausch + Lomb's (BLCO.TO) next earnings date is currently unknown.
-
Does Bausch + Lomb pay dividends?
No, Bausch + Lomb does not pay dividends.
-
How much money does Bausch + Lomb make?
Bausch + Lomb has a market capitalization of 8.97B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 10.03% to 4.15B US dollars. Bausch + Lomb made a loss 260M US dollars in net income (profit) last year or $0.07 on an earnings per share basis.
-
What is Bausch + Lomb's stock symbol?
Bausch + Lomb Corporation is traded on the TSX under the ticker symbol "BLCO.TO".
-
What is Bausch + Lomb's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of Bausch + Lomb?
Shares of Bausch + Lomb can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Bausch + Lomb have?
As Jul 2024, Bausch + Lomb employs 13,300 workers.
-
When Bausch + Lomb went public?
Bausch + Lomb Corporation is publicly traded company for more then 3 years since IPO on 6 May 2022.
-
What is Bausch + Lomb's official website?
The official website for Bausch + Lomb is bausch.com.
-
Where are Bausch + Lomb's headquarters?
Bausch + Lomb is headquartered at 520 Applewood Crescent, Vaughan, ON.
-
How can i contact Bausch + Lomb?
Bausch + Lomb's mailing address is 520 Applewood Crescent, Vaughan, ON and company can be reached via phone at +90 56957700.
Bausch + Lomb company profile:
Bausch + Lomb Corporation
bausch.comTSX
13,000
Medical - Instruments & Supplies
Healthcare
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Vaughan, ON L4K 4B4
:
ISIN: CA0717051076
:
